Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 01-Jul 2024. Module: IPS terminology module (core metadata concept)
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3682655012 | Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 3682657016 | Isoniazid 50 mg and pyrazinamide 300 mg and rifampin 120 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| 3682658014 | Isoniazid 50 mg and pyrazinamide 300 mg and rifampicin 120 mg oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | IPS terminology module (core metadata concept) |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Is a | Isoniazid and pyrazinamide and rifampicin only product | true | Inferred relationship | Some | ||
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Pyrazinamide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 1 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Pyrazinamide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Rifampicin | true | Inferred relationship | Some | 2 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 2 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Rifampicin | true | Inferred relationship | Some | 2 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Isoniazid (substance) | true | Inferred relationship | Some | 3 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | true | Inferred relationship | Some | 3 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 3 | |
| Product containing precisely isoniazid 50 milligram and pyrazinamide 300 milligram and rifampicin 120 milligram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Isoniazid (substance) | true | Inferred relationship | Some | 3 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Reference Sets
FHIR